FFS: An end(point) to our problems in chronic GVHD trials?

Abstract

In this issue of Blood, Inamoto et al provide encouragement that we are reaching the time where we have a robust endpoint to use in large, randomized clinical trials testing novel agents in chronic graft-versus-host disease (GVHD). © 2014 by The American Society of Hematology.